TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11304721
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg of naproxen sodium with 50 mg of diphenhydramine hydrochloride
Study: 1430394
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of MPI 5003
Study: 1430394
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of MPI 5003
Study: 18711764
Drug: Mitomycin (MMC)
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 with Kanglaite (KLT) 100 ml intravenously per day on days 1 to 14 every 3 weeks
Study: 18711764
Drug: Mitomycin (MMC)
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 without Kanglaite (KLT)
Study: 18711764
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with clinical benefit from chemotherapy
Study: 15918104
Drug: Dual RAAS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual RAAS blockade (angiotensin II receptor blocker + ACE inhibitor)
Study: 12971702
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy (intervention group)
Study: 12971702
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group therapy
Study: 12971702
Drug: Total amount
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total amount of inpatient physiotherapy and occupational therapy received by the intervention group
Study: 11009238
Drug: Plain mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain mixture LBH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL isotonic saline)
Study: 11009238
Drug: pH-adjusted mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-adjusted mixture LBH-PH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL sodium bicarbonate 8.4%)
Study: 8769362
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administration (0.1 IU/kg.d)
Study: 8769362
Drug: T3 administration
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 administration (40 micrograms on even dates or 20 micrograms on uneven dates)
Study: 1532948
Drug: 40% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% urea ointment with 1% bifonazole (group A)
Study: 1532948
Drug: 40% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% urea ointment with 1% bifonazole and oral griseofulvin 500 mg/day (group B)
Study: 1532948
Drug: Oral griseofulvin
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral griseofulvin alone
Study: 25523961
Drug: Subgingival mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival mechanical therapy with azithromycin
Study: 25523961
Drug: Subgingival mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival mechanical therapy with placebo
Study: 22297666
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (target range 80–110 mg/dl)
Study: 22297666
Drug: Conservative glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative glycemic control (target range 140–180 mg/dl)
Study: 10811588
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with standard aspirin and beta-blockade
Study: 8979037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both systems
Study: 1599892
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of morphine in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 1, n = 40)
Study: 1599892
Drug: Saline in
Normalized name: Simply Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 2, n = 42)
Study: 3881447
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment in a plaster cast
Study: 28214082
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (6mg/h)
Study: 26177235
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS (n = 10), 1200 pulses at 1 Hz for 20 min, five daily sessions over the contralesional motor cortex.
Study: 17305206
Drug: Justice-based service
Approvals — FDA: no, EMA: no, PMDA: no
Description: Justice-based service recovery strategies (interactional justice, distributive justice, and combination)
Study: 7572582
Drug: Mibefradil 25
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 25 mg
Study: 9286850
Drug: Mibefradil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (all doses)
Study: 9286850
Drug: Mibefradil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (50 mg and 100 mg)
Study: 3534592
Drug: L-PAM (melphalan)
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM (melphalan) for 2 years
Study: 29198406
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (no aliskiren treatment)
Study: 28664839
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 µg/day for 24 weeks)
Study: 18413499
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 4 weeks
Study: 18413499
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no CPAP therapy)
Study: 10762497
Drug: Remacemide 600
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide 600 mg daily for 5 weeks
Study: 10762497
Drug: Remacemide 150
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide 150 mg or 300 mg daily for 5 weeks
Study: 7848615
Drug: Lisinopril (Women)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (Women)
Study: 7848615
Drug: Lisinopril (Men)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (Men)
Study: 2904203
Drug: topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical timolol and betaxolol
Study: 25853697
Drug: Endobronchial Coils
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial Coils treatment
Study: 21225292
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 0.5% ropivacaine plus 25 μg fentanyl (group RF)
Study: 21225292
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg 0.75% levobupivacaine plus 25 μg fentanyl (group LF)
Study: 15454352
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg/day)
Study: 9709140
Drug: Vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium bromide 0.25 ml (0.5 mg)
Study: 9709140
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 0.25 ml
Study: 8574271
Drug: Oral oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxandrolone (ASOX)
Study: 8574271
Drug: Parenteral nandrolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nandrolone decanoate (ASND)
Study: 31272550
Drug: Rituximab 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 1,000 mg intravenous on days 0 and 12 post-transplant
Study: 28948482
Drug: Single 90-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 90-mg dose of hydrocodone ER under fed conditions
Study: 28948482
Drug: Single 90-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 90-mg dose of hydrocodone ER under fasted conditions
Study: 28948482
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of hydrocodone ER (45 mg twice daily on days 2-3, 60 mg twice daily on days 4-5, 90 mg twice daily on days 6-10, and 90 mg once in the morning on day 11) under fed conditions
Study: 28948482
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of hydrocodone ER under fasted conditions
Study: 21661100
Drug: Aspart insulin
Normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aspart insulin protocol every 2 hours when BG > 200 mg/dL, and if admitted, began daily detemir in the ED
Study: 21661100
Drug: Aspart insulin
Normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aspart insulin protocol
Study: 11087767
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean dose, 1.8 mg/d)
Study: 11087767
Drug: Trazodone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (mean dose, 200 mg/d)
Study: 7084867
Drug: Irradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation therapy combined with vitamin A palmitate (1.5 mill. I.U./day; total dose: 30 mill. I.U.), applied orally
Study: 30204741
Drug: Topical decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decolonization with nasal mupirocin and chlorhexidine body wash
Study: 26967008
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid intake after tonsillectomy (mean 18.2 mL/kg, SD 10.8 mL/kg)
Study: 22794154
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clozapine (100 mg)
Study: 22794154
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clozapine (100 mg)
Study: 22794154
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference formulations of clozapine
Study: 11886002
Drug: Treosulfan 7
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Treosulfan 7 g/m2 infused over 30 min, repeated every 4 weeks
Study: 11886002
Drug: Leuprorelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 3.75 mg injected subcutaneously or intramuscularly, repeated every 4 weeks
Study: 10082251
Drug: Antiepilepsirine (AES)
Normalized name: Ae-turmeric
DrugBank: Ilepcimide (DB16942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepilepsirine (AES) 10 mg/kg per day
Study: 6349650
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (300 mg per day for a maximum of 3 weeks)
Study: 6349650
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg per day)
Study: 10567956
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg injections, one prior to surgery and one on Day 4 posttransplant)
Study: 8671319
Drug: 75 microgram
Normalized name: Norgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microgram dose of desogestrel
Study: 8671319
Drug: 30 microgram
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microgram dose of desogestrel
Study: 8671319
Drug: 50 microgram
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microgram dose of desogestrel
Study: 1751794
Drug: Epoetin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (all doses combined)
Study: 6753888
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide phosphate (loading dose of 150, 200, or 300 mg followed by maintenance doses of 100, 150, or 200 mg every 6 hours based on weight)
Study: 27844152
Drug: Clinician-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-directed therapy (n = 26)
Study: 27844152
Drug: SwallowIT-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SwallowIT-assisted therapy (n = 26)
Study: 27844152
Drug: Patient-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-directed therapy (n = 27)
Study: 24593317
Drug: Alcohol-free essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free essential oil mouthwash (AF-EOMW) used twice a day
Study: 21380536
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment (630-670 nm, 1.875 J/cm²) plus scaling and root planing (SRP) for five consecutive days
Study: 21380536
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment (630-670 nm, 1.875 J/cm²) plus scaling and root planing (SRP) for ten consecutive days
Study: 19056656
Drug: Spread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread with plant sterol esters (1.1 g/d or 2.2 g/d plant sterols; n = 120)
Study: 17888974
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mitral surgery alone or medical therapy)
Study: 15002024
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice daily (0800 and 2000 hours)
Study: 8011964
Drug: Caplet formulation
Normalized name: Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplet formulation (product A)
Study: 8011964
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation (product B)
Study: 28800765
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil administered preoperatively (n=16)
Study: 28800765
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil administered post-MTS (n=14)
Study: 22397878
Drug: High-CHO/low-GI diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CHO/low-GI diet (L)
Study: 12538184
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution dorsal penile block
Study: 8803517
Drug: FK-224 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK-224 (2 mg)
Study: 1611544
Drug: tyrosine-adsorbed Dermatophagoides
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tyrosine-adsorbed Dermatophagoides pteronyssinus vaccine
Study: 29258367
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 6 months
Study: 25130052
Drug: Oxymorphone (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone (10, 20, and 40 mg)
Study: 25130052
Drug: Oxymorphone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone (40 mg)
Study: 25130052
Drug: Oxycodone (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10, 20, and 40 mg)
Study: 24800725
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 20 mg/month
Study: 24800725
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 40 mg/month
Study: 24800725
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 60 mg/month
Study: 10699346
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa OMPs vaccine
Study: 9356538
Drug: Medium-protein diet
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-protein diet (1.0 g/kg)
Study: 3780124
Drug: Diazepam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.15 and 0.30 mg/kg)
Study: 1294894
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg)
Study: 3780124
Drug: Buspirone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone + Diazepam (0.30 mg/kg)
Study: 3936091
Drug: Diazepam (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.30 mg/kg)
Study: 25266547
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 441 mg IM in the deltoid
Study: 25266547
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 441 mg IM in the gluteal
Study: 25266547
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 441 mg IM in the deltoid or gluteal
Study: 22382362
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 or 10 mg/kg every 3 weeks for four doses followed by maintenance dosing
Study: 28422751
Drug: Ipilimumab treatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab treatment
Study: 20067654
Drug: Surgical or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical or catheter interventional treatment of coarctation
Study: 18837100
Drug: Purgative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purgative preparation
Study: 16428147
Drug: Silicic acid
Normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicic acid applied twice daily for 8 weeks
Study: 10229307
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g oral glucose tolerance test (OGTT)
Study: 8902442
Drug: 3 mg/day
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/day E2 cream continuously for 12 months
Study: 1906893
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol administration
Study: 1906893
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol administration
Study: 1906893
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (oral and transdermal)
Study: 11575229
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg (V+H)
Study: 8988832
Drug: Flurbiprofen 1
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 1 mg.kg-1
Study: 8988832
Drug: Flurbiprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 0.5 mg.kg-1
Study: 2891316
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine (ocular)
Study: 2891316
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine (nasal)
Study: 2891316
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine (nasal and ocular)
Study: 30236511
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg orally daily for 24 weeks)
Study: 26966279
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 100 mg/d
Study: 12833113
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg sibutramine for 14 days
Study: 12833113
Drug: 10 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 months open treatment with 15 mg sibutramine and dietary advice
Study: 9798779
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative intraperitoneal chemotherapy (EPIC) with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5
Study: 28119434
Drug: Early group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early group (intravenous edaravone [30 mg] started before or during tPA)
Study: 22321227
Drug: High hs-CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hs-CRP group (hs-CRP ≥ 3 mg/L)
Study: 22321227
Drug: Moderate hs-CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hs-CRP group (hs-CRP 1-3 mg/L)
Study: 22321227
Drug: Normal hs-CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hs-CRP group (hs-CRP < 1 mg/L)
Study: 22321227
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin (20 mg)
Study: 22321227
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin (40 mg)
Study: 19382480
Drug: Maren Zipi
Normalized name: 3-carene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maren Zipi pill (Control)